StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) stock

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.15−0.04 (-1.83%)

Close on Nov 16, 2026Market cap $93.09MP/E –Yield –

NRX Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

NRX Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$19.70M. For fiscal 2025 it was -$16.15M.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.15M–
FY2024Dec 31, 2024-$18.50M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.44M–
Q1 FY2026Mar 31, 2026-$4.68M–
Q4 FY2025Dec 31, 2025-$4.58M–
Q3 FY2025Sep 30, 2025-$4.00M–
Q2 FY2025Jun 30, 2025-$3.73M–
Q1 FY2025Mar 31, 2025-$3.85M–
Q4 FY2024Dec 31, 2024-$2.43M–
Q3 FY2024Sep 30, 2024-$3.02M–

More NRX Pharmaceuticals figures

See a number that looks wrong?